Additional Supporting Information may be found in the online version of this article at the publisher's web-site.

jcph189-sm-0001-SupFig-S1.eps1361KFigure S1. Scatter plots of the relationship between renal clearance and pharmacokinetic variables related to dalfampridine 7.5-mg exposure under steady-state conditions: Group 1 = subjects with no renal impairment (○); Group 2 = subjects with mild renal impairment (Δ); and Group 3 = subjects with moderate renal impairment (□). Panels A and B demonstrate maximum plasma concentration (Cmax). Panels C and D show the area under the plasma concentration curve over 1 dosing interval of 12 hours (AUC0–12). Panels E and F illustrate the total body clearance (CL/F) corrected for bioavailability. *P < .0001.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.